alemtuzumab sold brand names campath lemtrada among others medication used treat chronic lymphocytic leukemia cll multiple cll used first line second line ms generally recommended treatments given injection monoclonal antibody binds protein present surface mature lymphocytes stem cells lymphocytes derived treatment alemtuzumab lymphocytes targeted destruction alemtuzumab approved medical use united states mabcampath withdrawn markets us europe prepare higherpriced relaunch lemtrada aimed multiple alemtuzumab used treatment bcell chronic lymphocytic leukemia bcll people treated alkylating agents failed fludarabine therapy unconjugated antibody thought work via activation antibodydependent cellmediated cytotoxicity used relapsing remitting form multiple cochrane metaanalysis studies comparing alemtuzumab interferon beta concluded annual cycles alemtuzumab probably reduces proportion people experience relapse may reduce proportion people experience disability worsening new lesions mri adverse events found similarly high however lowtomoderate levels evidence included existing studies noted need larger highquality randomised controlled trials comparing mono combination therapy alemtuzumab generally recommended people respond sufficiently least two ms alemtuzumab contraindicated patients active infections underlying immunodeficiency eg seropositive hiv known type hypersensitivity anaphylactic reactions november us food drug administration fda issued safety warning rare serious instances stroke blood vessel wall tears multiple sclerosis patients received lemtrada alemtuzumab mostly occurring within day initiating treatment leading cases permanent disability even death addition cases fda safety announcement refers cases spontaneous intracranial haemorrhage retrospectively identified four us multiple sclerosis centres correspondence published online february april pharmacovigilance risk assessment committee prac european medicines agency ema reported started review multiple sclerosis medicine lemtrada alemtuzumab following new reports immunemediated conditions problems heart blood vessels medicine including fatal cases prac advised review ongoing lemtrada started adults relapsingremitting multiple sclerosis highly active despite treatment least two diseasemodifying therapies type multiple sclerosis medicine diseasemodifying therapies used prac advised patients treated lemtrada benefitting may continue treatment consultation common adverse reactions associated alemtuzumab infusion ms patients include upper respiratory tract urinary tract infections herpes virus infections lymphopenia leucopenia changes thyroid function tachycardia skin rashes pruritus pyrexia summary product characteristics provided electronic medicines compendium emc lists common uncommon adverse reactions reported lemtrada include serious opportunistic nocardial infections cytomegalovirus alemtuzumab also precipitate autoimmune disease suppression regulatory cell populations andor emergence autoreactive cases multiple sclerosis reactivationrelapse also alemtuzumab recombinant dnaderived humanized kappa monoclonal antibody directed cell surface glycoprotein invitro experiment shown alemtuzumab antiviral properties origins alemtuzumab date back derived rat antibodies raised human lymphocyte proteins herman waldmann colleagues name campath derives pathology department cambridge university initially ideal therapy patients could theory react foreign rat protein determinants antibody circumvent problem greg winter colleagues humanised extracting hypervariable loops specificity grafting onto human antibody framework became known serves basis alemtuzumab started life laboratory tool understanding immune system within short time clinically investigated use improve success bone marrow transplants treatment leukaemia lymphoma vasculitis organ transplants rheumatoid arthritis multiple campath medication first approved bcell chronic lymphocytic leukemia marketed genzyme acquired worldwide rights bayer ag genzyme bought sanofi augustseptember campath withdrawn markets us europe done prevent offlabel use drug treat multiple sclerosis prepare relaunch trade name lemtrada different dosage aimed multiple sclerosis treatment expected much bayer reserves right copromote lemtrada years option renew additional five years february sanofiaventis since renamed sanofi acquired genzyme manufacturer acquisition delayed dispute two companies regarding value alemtuzumab dispute settled issuance contingent value rights type stock warrant pays dividend alemtuzumab reaches certain sales targets contingent value rights cvr trade nasdaqgm market ticker symbol gcvrz august genzyme surrendered licence presentations pending regulatory approval reintroduce treatment multiple sclerosis genzyme would later bring market product much higher price proved correct retrospective study alemtuzumab mg iv weekly patients controls severe steroidresistant acute intestinal graftversushost disease allogeneic hematopoietic stem cell transplantation hsct demonstrated improvement overall response rate complete response study median survival days important complications following treatment included cytomegalovirus reactivation bacterial infection invasive aspergillosis httpsenwikipediaorgwikialemtuzumab